Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 5

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Bilen, Ozlem, Adler, Arnon, Bastiaenen, Rachel, MacNamara, James P., Paratz, Elizabeth, Maor, Elad, Arad, Michael, Gold, Matthew, Patel, Nirav, Pruett, Cliff, Burford, Edward, Arora, Garima, Maksabedian Hernandez, Ervant J., Han, Xu, Schuler, Patricia, Sandler, Belinda, Li, Leanne, Tian, Dajun, Arora, Pankaj, on behalf of the COLLIGO-HCM investigators·2026·Circulation: Genomic and Precision Medicine

Abstract

BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II–III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy). METHODS: Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for inclusion if they had ≥1 mavacamten prescription after the date of diagnosis. Patients were categorized based on background therapy status during mavacamten treatment: mavacamten monotherapy or mavacamten with background therapy (down-titration or no dose modification). RESULTS: Overall, 278 patients were included and received mavacamten (mavacamten monotherapy, n=88; mavacamten with background therapy, n=190). At month 9, most patients achieved ≥1 New York Heart Association class improvement from baseline (mavacamten monotherapy, 60.0%; mavacamten with background therapy, 61.0%). Improvements in resting and Valsalva left ventricular outflow tract gradients from baseline to month 9 were observed in both subgroups; mean left ventricular ejection fraction through month 9 remained ≥62.0% with mavacamten monotherapy and ≥61.4% with mavacamten with background therapy. Two patients in the mavacamten monotherapy subgroup and 1 patient in the mavacamten with background therapy subgroup permanently discontinued treatment owing to left ventricular ejection fraction <50%. CONCLUSIONS: Mavacamten monotherapy was associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over a 9-month follow-up period; this was consistent with improvements observed in patients treated with mavacamten with background therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06372457.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circgen.125.005502

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Change in New York Heart Association (NYHA) class from baseline to the most recent visit up to month 9. The change in NYHA class status of each patient up to their most recent visit is included. Symmetry tests were conducted to compare measures between baseline and month 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.
Figure 1. Change in New York Heart Association (NYHA) class from baseline to the most recent visit up to month 9. The change in NYHA class status of each patient up to their most recent visit is included. Symmetry tests were conducted to compare measures between baseline and month 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.CC BY-NC-ND · PubMed Central
Figure 2. Resting and Valsalva left ventricular outflow tract (LVOT) gradients over time. Data presented are mean (SD). The dotted lines represent 30 mm Hg (A) and 30 mm Hg and 50 mm Hg (B) LVOT gradient thresholds. Paired t tests were conducted to compare within-group differences in LVOT gradient between baseline and months 3, 6, and 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.
Figure 2. Resting and Valsalva left ventricular outflow tract (LVOT) gradients over time. Data presented are mean (SD). The dotted lines represent 30 mm Hg (A) and 30 mm Hg and 50 mm Hg (B) LVOT gradient thresholds. Paired t tests were conducted to compare within-group differences in LVOT gradient between baseline and months 3, 6, and 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.CC BY-NC-ND · PubMed Central
Figure 3. Left ventricular ejection fraction (LVEF) over time. Data presented are mean (SD). The dotted line represents the 50% threshold under which treatment is interrupted per protocol. Paired t-tests were conducted to compare within-group differences in LVEF between baseline and months 3, 6, and 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.
Figure 3. Left ventricular ejection fraction (LVEF) over time. Data presented are mean (SD). The dotted line represents the 50% threshold under which treatment is interrupted per protocol. Paired t-tests were conducted to compare within-group differences in LVEF between baseline and months 3, 6, and 9. COLLIGO-HCM indicates Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 5

Metadata

Authors
Bilen, O., Adler, A., Bastiaenen, R., MacNamara, J. P., Paratz, E., Maor, E., Arad, M., Gold, M., Patel, N., Pruett, C., Burford, E., Arora, G., Maksabedian Hernandez, E. J., Han, X., Schuler, P., Sandler, B., Li, L., Tian, D., Arora, P., & on behalf of the COLLIGO-HCM investigators
Affiliations
  • Department of Medicine, Emory University, Atlanta, GA (O.B., M.G.).
  • University Health Network and Department of Medicine, Peter Munk Cardiac Centre, University of Toronto, Ontario, Canada (A.A.).
  • Cardiology Department, Guy’s &amp; St Thomas’ NHS Foundation Trust, London, United Kingdom (R.B., E.B.).
  • University of Texas Southwestern Medical Center, Dallas (J.P.M., C.P.).
  • The Alfred Hospital, Melbourne, Victoria, Australia (E.P.).
  • Heart Failure Institute, Sheba Medical Center, Ramat Gan, Israel (E.M., M.A.).
  • University of Alabama at Birmingham (N.P., G.A., P.A.).
  • Bristol Myers Squibb, Princeton, NJ (E.J.M.H., X.H., P.S.).
  • Bristol Myers Squibb, Uxbridge, United Kingdom (B.S.).
  • IQVIA, Durham (L.L., D.T.).
Venue
Circulation: Genomic and Precision Medicine
Published
2026-02
Volume
19
Issue
1
ISSN
2574-8300
Cited by
5
References
17
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
Funders
Bristol-Myers Squibb (N/A)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. https://app.cochat.ai/papers/10.1161/circgen.125.005502
The paper
Bilen, O., Adler, A., Bastiaenen, R., MacNamara, J. P., Paratz, E., Maor, E., Arad, M., Gold, M., Patel, N., Pruett, C., Burford, E., Arora, G., Maksabedian Hernandez, E. J., Han, X., Schuler, P., Sandler, B., Li, L., Tian, D., Arora, P., & on behalf of the COLLIGO-HCM investigators. (2026). Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.